BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jablonka S, Hennlein L, Sendtner M. Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders. Neurol Res Pract 2022;4:2. [PMID: 34983696 DOI: 10.1186/s42466-021-00162-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Kokorina AA, Nikitin SS. Interim Analysis of Treatment Outcomes of Young Children with 5q Spinal Muscular Atrophy on Gene Replacement Therapy with Onasemnogene Abeparvovec. Clinical Observations. Vopr sovr pediatr 2023. [DOI: 10.15690/vsp.v21i6s.2497] [Reference Citation Analysis]
2 Giovannelli I, Higginbottom A, Kirby J, Azzouz M, Shaw PJ. Prospects for gene replacement therapies in amyotrophic lateral sclerosis. Nat Rev Neurol 2023;19:39-52. [PMID: 36481799 DOI: 10.1038/s41582-022-00751-5] [Reference Citation Analysis]
3 Minear MA, Phillips MN, Kau A, Parisi MA. Newborn screening research sponsored by the NIH : From diagnostic paradigms to precision therapeutics. American J of Med Genetics Pt C 2022. [DOI: 10.1002/ajmg.c.31997] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Walter MC, Hiebeler M. Spinale Muskelatrophie im Erwachsenenalter. Fortschr Neurol Psychiatr 2022;90:421-430. [DOI: 10.1055/a-1801-3785] [Reference Citation Analysis]
5 Vinay V, Verma P, Munjal S, Kanna MD, Jain S, Arunachalam M. Respiratory failure in spinal muscular atrophy: A case report and review of literature. J Prim Care Spec 2022;0:0. [DOI: 10.4103/jopcs.jopcs_18_22] [Reference Citation Analysis]
6 Meyer-lindenberg A, Dickson SL, Millan MJ, Knudsen GM. Prospects for improved prevention and treatment of neuropsychiatric disorders: Neuroscience Applied. Neuroscience Applied 2022;1:100103. [DOI: 10.1016/j.nsa.2022.100103] [Reference Citation Analysis]